5 recent changes:
- CMS caps out-of-pocket insulin costs for Medicare
CMS is limiting out-of-pocket insulin costs for Medicare beneficiaries to $35 per month. - CMS proposes payment boost for CAR-T therapies
CMS proposed a payment increase for hospitals administering CAR-T therapy treatments in response to criticism that CAR-T costs aren’t sustainable for hospitals. - CMS allows pharmacies to bill Medicare for COVID-19 tests
CMS implemented a temporary policy that allows pharmacies to bill Medicare for COVID-19 tests, a move that could increase the number of pharmacies able to offer diagnostic testing. - New CMS rule could raise out-of-pocket drug costs
CMS announced a rule going into effect in July that likely will raise out-of-pocket drug costs for many consumers. - CMS cleared to survey 340B hospitals on their drug acquisition costs
CMS received final approval to conduct a survey to collect drug acquisition costs for hospitals in the 340B drug-pricing program, a survey hospitals in the program have strongly opposed.
More articles on pharmacy:
6 BCBS companies sue CVS, claiming decadelong insurance fraud scheme
FDA finds carcinogen in popular diabetes drug
Georgia pharma company recalls thyroid drug for super potency
